Diag2Tec Patents and Publications

Diag2Tec Patents and Publications 2016-10-24T15:19:26+00:00

Patents & Publications

DNMTi: Decitabine (Dacogen®) / Azacitidin (Vidaza®)

  • Moreaux and al “Gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors.” Mol Cancer Ther. 2012 Dec; 11;(12):2685-92.
  • Moreaux and al “DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine.” Br J Haematol. 2014 Feb;164(4):613-6.
  • Patent : Method for predicting multiple myeloma treatment response. Moreaux J, Klein B. EP12306141.8, 2012.

HDACi : TSA / Valproic Acid / Panobinostat (Farydak®) / Vorinostat-SAHA (Zolinza®)

  • Moreaux and al “Gene expression based prediction of myeloma cell sensitivity to histone deacetylase inhibitors.” British Journal of Cancer. 2013 Aug 6;109(3):676-85.
  • Patent : Method for predicting HDACi treatment response in Multiple Myeloma. Moreaux J, Klein B. EP12306225.9, 2012.

DNMTi + HDACi

  • Article in submission
  • Patent : Method for predicting DNMTi/HDACi combination treatment response in Multiple Myeloma. Moreaux J, Klein B. EP14305404, 2014.

DNA repair pathway score

  • Kassambara and al ”A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy” Oncotarget. 2014 May 15;5(9):2487-98.
  • Moreaux and al « Identification of a 20 gene expression based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients  » Biomed Res Int.2014;2014:423174.
  • Moreaux and al « Gene expression based risk score in diffuse large B cell lymphoma » Oncotarget. 2012 Dec;3(12): 1700-10.
  • Patent : Methods for predicting response to DNA repair pathway inhibitors in diffuse large B-cell lymphoma. Moreaux J, Bret C, Cartron G, Constantinou A, Pasero P. EP14306201. 2014.